MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Horizon Therapeutics Public Limited Company ROE Ratio 2011-2026 | HZNP
Annual ROE Ratio Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.28 | 11.44 | 9.68 | 26.22 | -3.64 | -35.33 | -13.1 | 3.01 | -48.8 | 303.58 | -82.84 | -246.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 303.58 | -246.7 | -5.52 |
Quarterly ROE Ratio Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.86 | 7.7 | 8.17 | 15.51 | 20.15 | 22.8 | 8.02 | 12.75 | 12.69 | 6.82 | 9.68 | 32.07 | 25.63 | 27.39 | 26.22 | 7.64 | 9.61 | 7.76 | -3.22 | -15.24 | -24.47 | -43.51 | -40.13 | -46.6 | -40.63 | -18.33 | -12.81 | -1.04 | -0.33 | 0.91 | 3.01 | -4.68 | -4.54 | -12.11 | -48.8 | 166.71 | 177.52 | 220.23 | 303.58 | 70.97 | 43.79 | -15.28 | -82.84 | -227.0 | -248.53 | -252.38 | -246.7 | -37.53 | -25.35 | -16.71 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 303.58 | -252.38 | -4.25 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.88 | -2.07 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
-86.96 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
22.71 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 102.06 | - | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.91 | 0.34 % | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
-41.09 | $ 0.79 | 1.28 % | $ 27.9 M | Israel |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.68 | -2.33 % | $ 112 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
529.06 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 1.06 | -2.75 % | $ 12.9 M | USA |